Form 4: Acurx Pharmaceuticals Director Carl Sailer Acquires Shares and Warrants in Direct Offering

Director Carl Sailer reports acquisition of Acurx Pharmaceuticals common stock and warrants through a registered direct offering and concurrent private placement.

Summary

• On January 6, 2025, Carl Sailer, a director of Acurx Pharmaceuticals, acquired 24,631 shares of common stock at a price of $1.015 per share.
• This acquisition was part of a registered direct offering by Acurx Pharmaceuticals.
• Sailer also acquired warrants for 24,631 shares of common stock at a price of $0 in a concurrent private placement.
• The warrants are exercisable from January 7, 2025, and expire on January 7, 2030, with an exercise price of $0.9.
• Following these transactions, Sailer directly owns 137,183 shares of common stock and indirectly owns 5,000 shares through a spouse.

Sentiment

Score: 7

Explanation: Director's purchase is a positive signal, but the context of a direct offering suggests the company may need capital.

Positives

• Director's purchase of shares and warrants may signal confidence in the company's future prospects.

Industry Context

Directors purchasing shares in their own company is generally viewed positively by the market, as it aligns their interests with those of other shareholders.

Stakeholder Impact

• The director's purchase could positively influence shareholder sentiment.
• The capital raise impacts shareholders through potential dilution.

Key Dates